Literature DB >> 25802306

Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?

Vinay Prasad1, Marie Diener-West2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25802306      PMCID： PMC4467955          DOI： 10.1503/cmaj.141627

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  18 in total

1.  Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-11-19       Impact factor: 25.391

2.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

Authors:  M C King; S Wieand; K Hale; M Lee; T Walsh; K Owens; J Tait; L Ford; B K Dunn; J Costantino; L Wickerham; N Wolmark; B Fisher
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

3.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Authors:  Andrew N Freedman; Barry I Graubard; Sowmya R Rao; Worta McCaskill-Stevens; Rachel Ballard-Barbash; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2003-04-02       Impact factor: 13.506

4.  Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.

Authors:  Elizabeth Maunsell; Paul E Goss; Rowan T Chlebowski; James N Ingle; José E Alés-Martínez; Gloria E Sarto; Carol J Fabian; Pascal Pujol; Amparao Ruiz; Andrew L Cooke; Susan Hendrix; Debra W Thayer; Kendrith M Rowland; Pierre Dubé; Silvana Spadafora; Sandhya Pruthi; Lavina Lickley; Susan L Ellard; Angela M Cheung; Jean Wactawski-Wende; Karen A Gelmon; Dianne Johnston; Andrea Hiltz; Michael Brundage; Joseph L Pater; Dongsheng Tu; Harriet Richardson
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

Review 5.  Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Authors:  M Levine; J M Moutquin; R Walton; J Feightner
Journal:  CMAJ       Date:  2001-06-12       Impact factor: 8.262

6.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

7.  Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk
Journal:  Breast       Date:  2014-12-06       Impact factor: 4.380

8.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

9.  Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.

Authors:  L S Donnelly; D G Evans; J Wiseman; J Fox; R Greenhalgh; J Affen; I Juraskova; P Stavrinos; S Dawe; J Cuzick; A Howell
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

10.  Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Authors:  Jack Cuzick; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell; John F Forbes
Journal:  Lancet Oncol       Date:  2014-12-11       Impact factor: 41.316
View more
  1 in total

Review 1.  Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.

Authors:  Veronica C Jones; Eric C Dietze; Tijana Jovanovic-Talisman; Jeannine S McCune; Victoria L Seewaldt
Journal:  Front Public Health       Date:  2020-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.